Related Experiment Videos
Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study
Khalifa E Sharquie1, Rafid A Najim, Ahmed R Abu-Raghif
1Department of Dermatology, College of Medicine, University of Baghdad, Iraq.
The Journal of Dermatology
|June 26, 2002
Summary
Dapsone effectively treats oral and genital ulcers in Behçet
Area of Science:
- Rheumatology
- Dermatology
- Immunology
Background:
- Behçet's disease is a chronic inflammatory disorder.
- Mucocutaneous manifestations are common in Behçet's disease.
Purpose of the Study:
- To evaluate dapsone's efficacy in treating Behçet's disease mucocutaneous symptoms.
- To assess dapsone's potential prophylactic role against disease manifestations.
Main Methods:
- Double-blind, placebo-controlled crossover trial.
- 20 patients with Behçet's disease received dapsone or placebo.
- Assessment of ulcers, cutaneous/systemic symptoms, pathergy test, and lab markers.
Main Results:
- Dapsone significantly reduced oral and genital ulcer parameters.
- Dapsone decreased other cutaneous and systemic manifestations.
- Dapsone improved pathergy test and laboratory results (ESR, CRP).
Conclusions:
- Dapsone is effective for mucocutaneous manifestations of Behçet's disease.
- Dapsone may offer prophylaxis against systemic Behçet's disease.
- Larger, longer studies are warranted.